Clinical Trial Goal
To find out if the combination of epcoritamab, rituximab and zanabrutinib is safe and works well to treat follicular lymphoma or MZL that has relapsed or is refractory
You may be able to join this trial if you:
- Are 18 years old or older
- Have one of the following hat has relapsed or is refractory:
- Follicular lymphoma, grades 1-3a
- MZL
- Have cancer cells with mutation/marker CD20 (CD20+). Your doctor can tell you this
- Do not have lymphoma in your brain or spinal cord
- Have not been treated with CAR T-cell therapy in the last 3 months
- Have not been treated with a drug that blocks BTK. Your doctor can tell you this
- Have not had an allogeneic (cells from a donor) blood or marrow transplant (BMT)
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Epcoritamab is a bispecific T-cell engager (BiTE) antibody that targets CD3 and CD20 on certain cells.
Rituximab is a monoclonal antibody that targets CD20 on certain cells.
Zanubrutinib is a small molecule inhibitor that blocks BTK in certain cells.
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
Rituximab is a monoclonal antibody that targets CD20 on certain cells.
Zanubrutinib is a small molecule inhibitor that blocks BTK in certain cells.
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
- Epcoritamab – Given as a shot under your skin. The dose you'll get depends on when you start the trial and how safe it has been
- Rituximab – Given as intravenous (IV) infusions. The dose you'll get depends on when you start the trial and how safe it has been
- Zanubrutinib – A pill that you take by mouth. The dose you'll get depends on when you start the trial and how safe it has been
You may continue treatment for up to 1 year. You'll have scans to see how well the treatment is working. The clinical trial doctors will check your health for up to 10 years.
The Food and Drug Administration (FDA) has approved epcoritamab and rituximab to treat follicular lymphoma and rituximab and zanubrutinib to treat MZL. Using them in this way to treat follicular lymphoma or MZL that has relapsed or is refractory is new and unproven.
Contacts
Reid Merryman, MD, 617-632-6844, Reid_merryman@dfci.harvard.edu
Heather A Walker, MPH, 857-215-1833, heathera_walker@dfci.harvard.edu
Locations
Dana-Farber Cancer InstituteRECRUITING
Boston, Massachusetts
Reid Merryman, MD, 617-632-6844, Reid_merryman@dfci.harvard.edu
Memorial Sloan Kettering Cancer CenterRECRUITING
New York, New York
Paola Ghione, MD, ghionep@mskcc.org
The Ohio State University Wexner Medical CenterRECRUITING
Columbus, Ohio
Aubree Shoemaker, Aubree.Shoemaker@osumc.edu
Sponsors
collaborator: BeiGene, collaborator: Genmab, lead: Reid Merryman, MD
